1. Home
  2. CVRX vs ICCC Comparison

CVRX vs ICCC Comparison

Compare CVRX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVRx Inc.

CVRX

CVRx Inc.

N/A

Current Price

$2.57

Market Cap

81.3M

Sector

Health Care

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$9.88

Market Cap

93.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CVRX
ICCC
Founded
2000
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.3M
93.1M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
CVRX
ICCC
Price
$2.57
$9.88
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $10.50
N/A
AVG Volume (30 Days)
★ 541.2K
12.4K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
23.02
★ 53.85
EPS
N/A
★ 0.41
Revenue
★ $56,651,000.00
$26,493,169.00
Revenue This Year
$17.17
N/A
Revenue Next Year
$17.69
N/A
P/E Ratio
★ N/A
$24.21
Revenue Growth
10.45
★ 51.64
52 Week Low
$2.20
$4.52
52 Week High
$11.30
$12.10

Technical Indicators

Market Signals
Indicator
CVRX
ICCC
Relative Strength Index (RSI) 35.30 41.20
Support Level $2.20 $9.39
Resistance Level $3.19 $10.16
Average True Range (ATR) 0.19 0.27
MACD 0.01 0.03
Stochastic Oscillator 9.68 32.86

Price Performance

Historical Comparison
CVRX
ICCC

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: